Literature DB >> 20105051

Protective effects of luteolin-7-O-beta-D-glucuronide methyl ester from the ethyl acetate fraction of Lycopi Herba against pro-oxidant reactive species and low-density lipoprotein peroxidation.

Min-Ja Lee1, Hye-Sook Lee, Sun-Dong Park, Hyung-In Moon, Won-Hwan Park.   

Abstract

In this study the potent scavenging activity of "Lycopi Herba" (LH) extract was studied using the following: evaluation of the total phenolics, measuring the antioxidant activity by Trolox equivalent antioxidant concentration, measuring the scavenging effects on reactive oxygen species, on reactive nitrogen species, and measuring the inhibitory effect on Cu(2+) induced human low-density lipoprotein oxidation in vitro. The ethyl acetate fraction from the LH extracts were found to have a potent scavenging activity against all of the reactive species tested, as well as an inhibitory effect on LDL oxidation. Therefore, we isolated and identified luteolin-7-O-beta-D-glucuronide methyl ester as the major compound from the ethyl acetate fraction of LH and their antioxidant activities were evaluated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20105051     DOI: 10.3109/14756360903524312

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  3 in total

Review 1.  The physiological basis of complementary and alternative medicines for polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Elisabet Stener-Victorin; XiaoKe Wu; Richard S Legro
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-12       Impact factor: 4.310

2.  Structural Characterization and Immunomodulatory Activity of a Novel Polysaccharide From Lycopi Herba.

Authors:  Wuxia Zhang; Yihua Hu; Jiaqi He; Dongdong Guo; Jinzhong Zhao; Peng Li
Journal:  Front Pharmacol       Date:  2021-06-25       Impact factor: 5.810

3.  The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial.

Authors:  Dong-Dong Xiao; Jian-Wei Lv; Xin Xie; Xing-Wei Jin; Mu-Jun Lu; Yuan Shao
Journal:  BMC Urol       Date:  2016-08-08       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.